FEops develops FEops HEARTguide, a cloud-based procedure planning environment that combines digital twin technology and artificial intelligence to model interactions between transcatheter structural heart devices and patient anatomy. The platform is CE-marked under MDR for TAVI and LAA workflows and FDA-cleared for the LAA workflow. FEops HEARTguide has been used for over 6,200 patients across 310 hospitals in 27 countries, and provides automated measurements and insights to improve procedure efficiency and clinical outcomes. The company says clinical data from the PREDICT-LAA randomized controlled trial show significant improvements in efficiency and outcomes for LAA occlusion procedures. FEops plans to expand its established digital twin technology into other indications and continue scaling its commercial and clinical footprint. The company is supported by Valiance Advisors, Capricorn Partners, PMV and the EIC Fund. FEops develops FEops HEARTguide, a cloud-based procedure planning environment that uses personalized computational modeling and simulation to predict interactions between transcatheter structural heart devices and patient anatomy. The current release includes workflows for transcatheter aortic valve implantation (TAVI) and left atrial appendage occlusion (LAAO). FEops HEARTguide received CE mark and approval for the Canadian market earlier this year. The company says it will use the Euro 3.2 million EIC grant to accelerate clinical evidence gathering, business implementation worldwide, and to extend device certifications. FEops is privately held and headquartered in Gent, Belgium, and its leadership includes co‑founder and CEO Matthieu De Beule and CFO Isabelle Decroos. In September 2017 FEops closed a €6 million financing led by Valiance with participation from Capricorn Venture Partners and PMV. FEops develops personalized computer simulations to improve structural heart interventions, focused on transcatheter valve therapies. Led by co-founder and CEO Matthieu De Beule, Ph.D., the company’s core product family is FEops HEARTguideTM. Its first product, TAVIguide™, is currently the only CE-marked technology that predicts how a TAVI implant will interact with patient-specific aortic anatomy and provides clinically meaningful insights for personalized device size selection and position. FEops’ proprietary system aims to improve procedural planning and outcomes for transcatheter valve procedures. The company intends to use recent funding to accelerate its product roadmap centered on FEops HEARTguide and to drive commercial adoption in the transcatheter valve market. Financial details of the fundraise are provided in the deal summary.

Total raised

$14M

Funding rounds

3

Latest round

Convertible Note

Latest activity

Oct 2022